Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
Location status: Recruiting
NCT Number: NCT04570163
The present study evaluates patients after interventional therapy of valvular diseases of the right heart. Follow-up examinations include medical history taking, laboratory measurements and an echo. The aim is to assess the different interventional therapies and their impact on patient's outcome.
Interested in participating?
Request Info18 year–120 year
All sexes
Observational
Berlin, 10117, Germany
Location status: Recruiting
The subject of the study is to register interventional therapies of right heart diseases (such as "cardioband" and "edge-to-edge" techniques of the tricuspid valve) performed in Berlin/ Brandenburg (primarily at the Charité, Universitätsmedizin Berlin). Based on the development and the increasing use of interventional therapies in tricuspid and pulmonary valve diseases, the impact on the patients' symptoms and life expectancy after interventions will be investigated. The aim is to identify patient subgroups that benefit the most.
Primary endpoints: Total mortality, cardiovascular mortality, heart failure hospitalization.
Secondary endpoints: NYHA class, NTproBNP, liver and kidney function (laboratory measurements), valve function, cardiac function, and cardiac morphology.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).
Time frame: 2 months after intervention
Number of deceased participants after 2 months after intervention
Time frame: 2 months after intervention
Number of deceased participants after 2 months after intervention (cardiovascular cause of mortality)
Time frame: 2 months after intervention
Number of participants with unscheduled hospitalization for heart failure progression after 2 months after intervention
Time frame: 2 months after intervention
New York Heart Association (NYHA) class (to rate dyspnea in heart failure patients)
Time frame: 2 months after intervention
Laboratory measurement of NTproBNP 2 months after intervention
Time frame: 2 months after intervention
Echocardiographic quantification of valve function (proximal isovelocity surface area [PISA] method, effective regurgitant orifice [ERO], vena contracta [VC]) after 2 months after intervention
Time frame: 2 months after intervention
Laboratory measurement of bilirubin 2 months after intervention
Time frame: 2 months after intervention
Laboratory measurement of creatinine 2 months after intervention
Time frame: 2 months after intervention
Echocardiographic measurement of cardiac function (left ventricular ejection fraction, tricuspid anular plane systolic excursion) after 2 months after intervention
Time frame: 2 months after intervention
Echocardiographic measurement of cardiac morphology (right ventricular and right atrial diameter) after 2 months after intervention
Contact information is provided by the study sponsor or research team.
Charite University, Berlin, Germany
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06183684
Cardiovascular Diseases, Heart Diseases
Tucson, Arizona, United States
View Trial DetailsNCT07171060
Cardiovascular Diseases, Heart Diseases
Ottawa, Ontario, Canada
View Trial DetailsNCT04097145
Cardiovascular Diseases, Heart Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT04433065
Cardiovascular Diseases, Heart Diseases
Birmingham, Alabama, United States
View Trial Details